| Previous Close | 4.2700 |
| Open | 4.4152 |
| Bid | 0.1000 x 2200 |
| Ask | 5.0000 x 3000 |
| Day's Range | 4.3300 - 4.7500 |
| 52 Week Range | 4.2800 - 8.4800 |
| Volume | 26,725 |
| Avg. Volume | 32,186 |
| Market Cap | 99.107M |
| Beta (3Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Mereo BioPharma Group plc (AIM: MPH, NASDAQ:MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces that the Trustee of the Mereo BioPharma Group plc Employee Benefit Trust (the “Trust”), Link Trustees (Jersey) Limited (the “Trustee”), has today indicated its intention to make market purchases of ordinary shares of the Company for the benefit of the Trust of up to £1,000,000 in aggregate amount, to help meet future obligations arising under the Company’s share schemes. It is expected that the Market Purchases will be funded by amounts advanced by the Company pursuant to a loan agreement dated the date hereof. The Trustee will make its trading decisions in relation to the Market Purchases independently of, and uninfluenced by, the Company.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW.
Mereo BioPharma Group plc("Mereo" or the "Company" or the "Group") LONDON, April 26, 2019 -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based,....
LONDON, April 24, 2019 -- Mereo BioPharma Group plc (AIM: MPH) (NASDAQ: MREO), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, today announces.